Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy.
arrhythmia
defibrillator
heart failure
implantable
sudden cardiac death
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
06
2020
accepted:
02
12
2020
revised:
11
11
2020
pubmed:
14
1
2021
medline:
23
12
2022
entrez:
13
1
2021
Statut:
ppublish
Résumé
Many patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) had a significant improvement (> 10%) in the left ventricular ejection fraction (LVEF) during the course of the study, but the factors and outcomes associated with such improvement are uncertain. We examined factors and rates of mortality, cause-specific mortality, and implantable cardioverter-defibrillator (ICD) shocks associated with improvement in LVEF by analyzing patients in the SCD-HeFT who were randomized to placebo or an ICD and who had an LVEF checked during follow-up. During a median follow-up of 3.99 years, of 837 patients who had at least two follow-up LVEF measurements, 276 (33%) patients had > 10% improvement in LVEF and 561 (67%) patients had no significant change in LVEF. Factors significantly associated with LVEF improvement included female sex, white race, history of hypertension, a QRS duration < 120 ms, and beta-blocker use. Improvement in LVEF was associated with a significant improvement in survival. There was no significant association between improvement in LVEF and cause-specific death, but there was a significant association between improvement in LVEF and reduced risk of receiving appropriate ICD shocks. About a third of patients in this analysis, who were randomized to placebo or an ICD in SCD-HeFT, had a significant improvement in LVEF during follow-up; improvement in LVEF was associated with improved survival but not with cause-specific death, and with decreased likelihood of receiving appropriate ICD shocks.
Sections du résumé
BACKGROUND
Many patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) had a significant improvement (> 10%) in the left ventricular ejection fraction (LVEF) during the course of the study, but the factors and outcomes associated with such improvement are uncertain.
METHODS
We examined factors and rates of mortality, cause-specific mortality, and implantable cardioverter-defibrillator (ICD) shocks associated with improvement in LVEF by analyzing patients in the SCD-HeFT who were randomized to placebo or an ICD and who had an LVEF checked during follow-up.
RESULTS
During a median follow-up of 3.99 years, of 837 patients who had at least two follow-up LVEF measurements, 276 (33%) patients had > 10% improvement in LVEF and 561 (67%) patients had no significant change in LVEF. Factors significantly associated with LVEF improvement included female sex, white race, history of hypertension, a QRS duration < 120 ms, and beta-blocker use. Improvement in LVEF was associated with a significant improvement in survival. There was no significant association between improvement in LVEF and cause-specific death, but there was a significant association between improvement in LVEF and reduced risk of receiving appropriate ICD shocks.
CONCLUSIONS
About a third of patients in this analysis, who were randomized to placebo or an ICD in SCD-HeFT, had a significant improvement in LVEF during follow-up; improvement in LVEF was associated with improved survival but not with cause-specific death, and with decreased likelihood of receiving appropriate ICD shocks.
Identifiants
pubmed: 33438181
pii: VM/OJS/J/69279
doi: 10.5603/CJ.a2020.0187
pmc: PMC9788743
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-984Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM007171
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM145449
Pays : United States
Références
J Am Coll Cardiol. 2020 Aug 11;76(6):719-734
pubmed: 32762907
J Am Coll Cardiol. 2015 Aug 4;66(5):524-31
pubmed: 26227190
Circulation. 2009 Dec 1;120(22):2170-6
pubmed: 19917887
Am Heart J. 2012 Jan;163(1):49-56.e2
pubmed: 22172436
J Clin Oncol. 2010 Jun 1;28(16):2796-801
pubmed: 20439643
N Engl J Med. 2012 Jan 26;366(4):291-3
pubmed: 22276818
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
J Card Fail. 2013 Jun;19(6):426-30
pubmed: 23743493
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283
pubmed: 26921377
Circulation. 2014 Jun 10;129(23):2380-7
pubmed: 24799515
Circ Heart Fail. 2016 Jul;9(7):
pubmed: 27413037
Circulation. 2018 Sep 25;138(13):e272-e391
pubmed: 29084731
Eur J Heart Fail. 2017 Dec;19(12):1615-1623
pubmed: 28387002
Eur Heart J. 2019 Jul 1;40(26):2110-2117
pubmed: 31280320
JAMA Cardiol. 2016 Aug 1;1(5):510-8
pubmed: 27434402
JAMA Cardiol. 2017 Jul 1;2(7):767-774
pubmed: 28724134
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
J Am Coll Cardiol. 2014 Jun 10;63(22):2388-94
pubmed: 24727249
Card Electrophysiol Clin. 2018 Mar;10(1):137-144
pubmed: 29428135
J Card Fail. 2011 Jul;17(7):527-32
pubmed: 21703523
Am Heart J. 2008 Jan;155(1):87-93
pubmed: 18082495
Heart Rhythm. 2013 Jun;10(6):838-46
pubmed: 23422221